Patents by Inventor Chien-Ming Li

Chien-Ming Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240310926
    Abstract: A composite function keyboard circuit includes a first matrix circuit, a first bias resistor group, a second matrix circuit, a second bias resistor group and a controller. Each switch unit in the first matrix circuit is an ink-type force sensing switch. A resistance of the ink-type force sensing switch is variable according to a pressing mode of a keypress action. An electrical connection path is formed between the ink-type force sensing switch and the corresponding bias resistor of the second bias resistor group. When the ink-type force sensing switch is electrically conducted, a divided sensing voltage is generated by the electrical connection path, and the controller generates a corresponding key control instruction according to a level of the divided sensing voltage. Furthermore, the cooperation of the first matrix circuit and the first bias resistor group can achieve a ghost key preventing function.
    Type: Application
    Filed: May 4, 2023
    Publication date: September 19, 2024
    Inventors: Yi-Liang Chen, Chih-Chen Chang, Chien-Ming Li
  • Publication number: 20220202823
    Abstract: Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof, contains an imidazole, or is miconazole or a salt thereof.
    Type: Application
    Filed: December 6, 2021
    Publication date: June 30, 2022
    Inventors: Yong HUANG, Dominique P. BRIDON, Xuexiang ZHANG, Chien-Ming LI
  • Patent number: 11197862
    Abstract: Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof contains an imidazole, or is miconazole or a salt thereof.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: December 14, 2021
    Assignee: XOMICS BIOPHARMA, INC.
    Inventors: Yong Huang, Dominique P. Bridon, Xuexiang Zhang, Chien-Ming Li
  • Patent number: 10865196
    Abstract: The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: December 15, 2020
    Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, ONCTERNAL THERAPEUTICS, INC.
    Inventors: Duane D. Miller, Jianjun Chen, James T. Dalton, Chien-Ming Li, Sunjoo Ahn, Wei Li
  • Patent number: 10301285
    Abstract: The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: May 28, 2019
    Assignees: GTX, INC., UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Duane D. Miller, Jianjun Chen, James T. Dalton, Chien-Ming Li, Sunjoo Ahn, Wei Li
  • Publication number: 20190092755
    Abstract: The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.
    Type: Application
    Filed: January 16, 2018
    Publication date: March 28, 2019
    Inventors: Duane D. MILLER, Jianjun CHEN, James T. DALTON, Chien-Ming LI, Sunjoo AHN, Wei LI
  • Publication number: 20180207169
    Abstract: Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof contains an imidazole, or is miconazole or a salt thereof.
    Type: Application
    Filed: July 15, 2016
    Publication date: July 26, 2018
    Inventors: Yong HUANG, Dominique P. BRIDON, Xuexiang ZHANG, Chien-Ming LI
  • Publication number: 20180093971
    Abstract: The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.
    Type: Application
    Filed: April 21, 2015
    Publication date: April 5, 2018
    Inventors: Duane D. Miller, Jianjun Chen, James T. Dalton, Chien-Ming Li, Sunjoo Ahn, Wei Li
  • Patent number: 9334242
    Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: May 10, 2016
    Assignees: GTX, INC., UNIVERSITY OF TENNESSEE
    Inventors: Yan Lu, Chien-Ming Li, Zhao Wang, Jianjun Chen, Wei Li, James T. Dalton, Duane D. Miller, Charles Duke, Sunjoo Ahn
  • Patent number: 9029408
    Abstract: The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: May 12, 2015
    Assignees: GTx, Inc., University of Tennessee Research Foundation
    Inventors: Duane D. Miller, Wei Li, Jianjun Chen, James T. Dalton, Chien-Ming Li, Sunjoo Ahn
  • Patent number: 8822513
    Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: September 2, 2014
    Assignees: GTX, Inc., University of Tennessee Research Foundation
    Inventors: Yan Lu, Chien-Ming Li, Zhao Wang, Jianjun Chen, Wei Li, James T. Dalton, Duane D. Miller, Charles Duke, Sunjoo Ahn
  • Publication number: 20140213623
    Abstract: The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.
    Type: Application
    Filed: October 9, 2013
    Publication date: July 31, 2014
    Applicants: GTx, Inc., University of Tennessee Research Foundation
    Inventors: Duane D. Miller, Li Wei, Jianjun Chen, James T. Dalton, Chien-Ming Li, Sunjoo Ahn
  • Patent number: 8592465
    Abstract: Compounds according to formula (I) are disclosed where Q is S, N, or O; X is optional, and can be O?, S?, ?N—NH2, ?N—OH, or —OH; Y is optional and can be —N(H)—, O, or C1 to C20 hydrocarbon; and R1 and R2 are each independently substituted or unsubstituted single-, fused- or multiple-ring aryl or (hetero)cyclic ring systems. Methods of making these compounds, pharmaceutical compositions containing the compounds, and their use, particularly for treating or preventing cancer, are also disclosed.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: November 26, 2013
    Assignees: University of Tennessee Research Foundation, The Ohio State University Research Foundation
    Inventors: Duane D. Miller, Wei Li, Zhao Wang, Yan Lu, Jianjun Chen, James T. Dalton, Chien-Ming Li
  • Patent number: 8498471
    Abstract: A method of identifying a wafer serial number is provided. First, a wafer having a wafer serial number is provided. Second, an identification procedure is carried out to identify the wafer serial number by means of multiple identification recipes thereby obtaining multiple digit results which correspond to the multiple identification recipes and a specific digit in the wafer serial number. The multiple digit results include at least two of a successful result and an unsuccessful result. Then, the wafer serial number is determined in accordance with the multiple digit results.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: July 30, 2013
    Assignee: Inotera Memories, Inc.
    Inventors: Wei-Chin Chen, Chien-Ming Li
  • Publication number: 20120071524
    Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.
    Type: Application
    Filed: August 24, 2011
    Publication date: March 22, 2012
    Inventors: Yan Lu, Chien-Ming Li, Zhao Wang, Jianjun Chen, Wei Li, James T. DALTON, Duane D. Miller, Charles Duke, Sunjoo Ahn
  • Publication number: 20110257196
    Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.
    Type: Application
    Filed: December 29, 2010
    Publication date: October 20, 2011
    Inventors: Yan Lu, Chien-Ming Li, Zhao Wang, Jianjun Chen, Wei Li, James T. Dalton, Duane D. Miller, Charles Duke, Sunjoo Ahn
  • Publication number: 20110123136
    Abstract: A method of identifying a wafer serial number is provided. First, a wafer having a wafer serial number is provided. Second, an identification procedure is carried out to identify the wafer serial number by means of multiple identification recipes thereby obtaining multiple digit results which correspond to the multiple identification recipes and a specific digit in the wafer serial number. The multiple digit results include at least two of a successful result and an unsuccessful result. Then, the wafer serial number is determined in accordance with the multiple digit results.
    Type: Application
    Filed: April 9, 2010
    Publication date: May 26, 2011
    Inventors: Wei-Chin Chen, Chien-Ming Li
  • Patent number: 7669498
    Abstract: A transmission system includes two or more independent chambers, in each of which shafts with gears thereon are provided for rolling in synchronous motion, and a carrier with adjustable gear devices on a bottom thereof. Each of the adjustable gear devices has a base, a movable rack member, vertical springs and horizontal springs. The movable rack member is connected to the base to be moved along a horizontal direction. The vertical springs are provided between the base and the carrier to urge the adjustable gear device along a vertical direction. The movable rack member has a rack portion to be meshed with the gears of the shafts, such that the carrier is moved by the gears to cross the chambers. With the movement of the movable rack member both along the horizontal and the vertical direction, the carrier is transported in a smooth, synchronous, skid-proof, stable and real-time motion during the crossing chamber process.
    Type: Grant
    Filed: August 10, 2005
    Date of Patent: March 2, 2010
    Assignee: Hsiuping Institute of Technology
    Inventors: Geeng-Jen Sheu, Tuan-Jen Yu, Chung-Chung Liu, Chien-Ming Li, Hsin-Lun Wu
  • Publication number: 20090326020
    Abstract: Compounds according to formula (I) are disclosed where Q is S, N, or O; X is optional, and can be O?, S?, ?N—NH2, ?N—OH, or —OH; Y is optional and can be —N(H)—, O, or C1 to C20 hydrocarbon; and R1 and R2 are each independently substituted or unsubstituted single-, fused- or multiple-ring aryl or (hetero)cyclic ring systems. Methods of making these compounds, pharmaceutical compositions containing the compounds, and their use, particularly for treating or preventing cancer, are also disclosed.
    Type: Application
    Filed: June 16, 2009
    Publication date: December 31, 2009
    Applicants: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Duane D. Miller, Wei Li, Zhao Wang, Yan Lu, Jianjun Chen, James T. Dalton, Chien-Ming Li
  • Publication number: 20070249083
    Abstract: A multilevel phase-change memory, operating method and manufacturing method thereof. The phase-change memory includes two phase-change layers and electrodes, which are configured in a parallel structure to form a memory cell. A voltage-drive mode is employed to control and drive the memory such that multilevel memory states may be achieved by imposing different voltage levels. The provided multilevel phase-change memory has more bits and higher capacity than that of the memory with a single phase-change layer.
    Type: Application
    Filed: June 25, 2007
    Publication date: October 25, 2007
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Chien-Ming Li, Wen-Han Wang, Kuei-Hung Shen